Dr Sridevi Khambhampaty appointed as CEO of Shilpa Biologicals

Karnataka: Shilpa Medicare has announced the appointment of Dr Sridevi Khambhampaty, as Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, a wholly-owned subsidiary of the Company.

"Dr. Sridevi Khambhampaty is a recognized leader in the Biologics industry with over two decades of expertise in developing products for the Indian, US and EU markets. In addition to her strong technical competence, she is regarded as an exceptional people leader who has consistently built high performing teams. Her deep understanding of the regulatory and compliance requirements of biologics development and manufacturing coupled with her business acumen make her highly suited for leading Shilpa Biologics into an extraordinary growth phase," the Company stated in a BSE filing.

Sridevi has a PhD in Biophysics from NCBS-TIFR Bangalore, and also has a postdoctoral fellowship from Stanford University, California. She brings an overall Techno Commercial experience of 22+ Years in various Organizations, notably in Lymphoma & Leukemia Research Foundation, Dr. Reddy’s, Intas Pharmaceuticals, her most recent assignment was with Syngene International Ltd.

Medical Dialogues team had earlier reported that the U.S. Food and Drug Administration (USFDA) had approved Shilpa Medicare's second NDA [505(b)(2)], injectable product - Bortezomib Injection. Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL).

Read also: Shilpa Medicare gets USFDA nod for Bortezomib Injection for multiple myeloma

Shilpa is an integrated pharmaceutical group with business interests in niche Oncology & Nononcology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.